Altered irinotecan metabolism in a patient receiving phenytoin

Ron H J Mathijssen; Alex Sparreboom; Herlinde Dumez; Allan T van Oosterom; Ernst A de Bruijn

doi:10.1097/00001813-200202000-00004

Altered irinotecan metabolism in a patient receiving phenytoin

Ron H J Mathijssen, Alex Sparreboom, Herlinde Dumez, Allan T van Oosterom, Ernst A de Bruijn

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38.

Original language	English
Pages (from-to)	139-40
Number of pages	2
Journal	Anti-Cancer Drugs
Volume	13
Issue number	2
DOIs	https://doi.org/10.1097/00001813-200202000-00004
Publication status	Published - Feb 2002

Access to Document

10.1097/00001813-200202000-00004

Cite this

@article{d7295660018f44b5a4707fd52cf54788,

title = "Altered irinotecan metabolism in a patient receiving phenytoin",

abstract = "The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38.",

author = "Mathijssen, {Ron H J} and Alex Sparreboom and Herlinde Dumez and {van Oosterom}, {Allan T} and {de Bruijn}, {Ernst A}",

year = "2002",

month = feb,

doi = "10.1097/00001813-200202000-00004",

language = "English",

volume = "13",

pages = "139--40",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

TY - JOUR

T1 - Altered irinotecan metabolism in a patient receiving phenytoin

AU - Mathijssen, Ron H J

AU - Sparreboom, Alex

AU - Dumez, Herlinde

AU - van Oosterom, Allan T

AU - de Bruijn, Ernst A

PY - 2002/2

Y1 - 2002/2

N2 - The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38.

AB - The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38.

U2 - 10.1097/00001813-200202000-00004

DO - 10.1097/00001813-200202000-00004

M3 - Article

C2 - 11901305

SN - 0959-4973

VL - 13

SP - 139

EP - 140

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 2

ER -

Altered irinotecan metabolism in a patient receiving phenytoin

Abstract

Access to Document

Fingerprint

Cite this